Remepy, a pioneer in hybrid drugs, announced that it closed a $10 million seed investment round, totaling $15 million when combined with earlier funding. This funding round was led by NFX and was joined by Vine Ventures, PsyMed Ventures, Supernode Ventures, and Firstime Ventures, while joining previous pre-seed lead investors TechAviv and Fresh.fund, Samsung Next, StageNext Fund, and 97212 Ventures.
Remepy’s new hybrid drugs combine traditional drugs with digital molecules. The digital molecules are therapeutic interventions that trigger physiological effects (aka MOAs, Mechanisms of Action) through the brain. These physiological changes have been known to enhance the effectiveness of traditional drugs.
These digital molecules are designed for hybrid drug experiences. They are based on noninvasive cognitive, psychological, and behavioral interventions that follow the principles of sensory integration, sensory substitution, and sensory deprivation. These interventions trigger multiple unique mechanisms of action, including changes to brain connectivity in important brain areas, changes to immune system blood biomarkers, and important behavioral changes.
Remepy has already demonstrated the effects of its digital molecule interventions in clinical trials using extensive fMRI imaging, blood and saliva samples analysis, and standardized questionnaires. And it is among the first in the world to show that its patent-pending digital therapies can modulate blood biomarkers.
Many diseases are also better treated by combining drugs with non-pharmacological interventions. And Remepy is making such combinations standardized, accessible and personalized at scale using its digital molecules.
Remepy targets neurodegenerative diseases, cancer, autoimmune diseases, and degenerative eye diseases. Its approach creates a new market for hybrid medications and a new world of data and IP assets for pharmaceutical companies.
KEY QUOTES:
“As a physician and drug developer, it is fascinating for me to see Remepy’s clinical data, which shows how these unique non-invasive digital interventions can modulate the immune system, make significant changes to brain plasticity, and drive behavioral changes. Remepy’s product has the potential to enhance immunotherapy for cancer, or improve existing drug therapy for neurodegenerative diseases such as Parkinson’s Disease and MCI (Mild Cognitive Impairment). These proprietary digital-drug combinations could significantly improve patient outcomes and create tangible value for patients and healthcare systems.”
- Dr. Danny Bar Zohar, Merck’s Global head of R&D and Chief Medical Officer
“I am thrilled that Dr. Danny Bar Zohar has joined us as a board member. Many industries have transformed by adopting a hybrid product approach, integrating new technology with traditional products.” Co-CEO Or Shoval added: “I am particularly excited about the prospects of improving Parkinson’s Disease patients’ lives with a hybrid PD drug that will better address cognitive, movement, speech, sleeping and psychological symptoms and has the potential of disease modification with changes to brain connectivity.”
- Dr. Michal Tsur, Remepy Co-CEO
“Remepy’s vision of enhancing drugs with digital companions is groundbreaking and their clinical proof that such enhancement is possible is incredibly exciting. Remepy has an experienced team of entrepreneurs and world-class scientists that are defining a new category in pharma.”
- Gigi Levy-Weiss, Managing Partner at NFX
